Vol 12, No 2 (2021)
Case report
Published online: 2021-11-30

open access

Page views 5873
Article views/downloads 279
Get Citation

Connect on Social Media

Connect on Social Media

Effective midostaurin treatment in a patient with aggressive systemic mastocytosis

Karolina Chromik1, Patrycja Rozwadowska2, Grzegorz Helbig1
Hematology in Clinical Practice 2021;12(2):72-76.


Systemic mastocytosis (SM) is a rare neoplastic disease of the hematopoietic system characterized by the presence of a somatic mutation in the KIT gene, leading to excessive proliferation of pathological mast cells. This results in abnormal growth of mast cells in the skin and other organs. There are following variants of SM: SM with an associated hematological neoplasm (SM-AHN), aggressive SM (ASM) and mast cell leukemia (MCL), they all are referred to as advanced SM (AdvSM). The drug of choice in the treatment of ASM in Poland is cladribine, which, however, is not approved in this indication, unlike the multikinase inhibitor — midostaurin and imatinib. The latter drug can be used when c-KIT D816V mutation remains negative or unknown.

A 61-year-old female with ASM, accompanied by pancytopenia, hepatosplenomegaly and bone marrow fibrosis with sclerotic bone lesions was reported. The patient was initially treated with cladribine, but due to lack of efficacy after 3 cycles, midostaurin was used as a second option. Initially, the patient developed neutropenia, which led to dose reduction. Treatment continuation resulted in improvement of blood counts and regression of organ changes. Finally, the patient achieved a partial response and the drug was well tolerated. Midostaurin remains a promising treatment option in a patient with ASM and cladribine ineffectiveness.

Article available in PDF format

View PDF Download PDF file


  1. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127(20): 2391–2405.
  2. Cohen SS, Skovbo S, Vestergaard H, et al. Epidemiology of systemic mastocytosis in Denmark. Br J Haematol. 2014; 166(4): 521–528.
  3. Garcia-Montero AC, Jara-Acevedo M, Teodosio C, et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood. 2006; 108(7): 2366–2372.
  4. Lim KH, Pardanani A, Butterfield JH, et al. Cytoreductive therapy in 108 adults with systemic mastocytosis: outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. Am J Hematol. 2009; 84(12): 790–794.
  5. Pieri L, Bonadonna P, Elena C, et al. Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients. Am J Hematol. 2016; 91(7): 692–699.
  6. Lim KH, Tefferi A, Lasho TL, et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood. 2009; 113(23): 5727–5736.
  7. Horny HP, Valent P, Horny HP, et al. Recent advances in mastocytosis research. Summary of the Vienna Mastocytosis Meeting 1998. Int Arch Allergy Immunol. 1999; 120(1): 1–7.
  8. Horny HP, Valent P, Horny HP, et al. Recent advances in mastocytosis research. Summary of the Vienna Mastocytosis Meeting 1998. Int Arch Allergy Immunol. 1999; 120(1): 1–7.
  9. Pardanani A, Tefferi A. Systemic mastocytosis in adults: a review on prognosis and treatment based on 342 Mayo Clinic patients and current literature. Curr Opin Hematol. 2010; 17(2): 125–132.
  10. Jawhar M, Schwaab J, Hausmann D, et al. Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis. Leukemia. 2016; 30(12): 2342–2350.
  11. Pardanani A, Shah S, Mannelli F, et al. Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models. Blood Adv. 2018; 2(21): 2964–2972.
  12. DeAngelo DJ, George TI, Linder A, et al. Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial. Leukemia. 2018; 32(2): 470–478.
  13. Pardanani A. Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management. Am J Hematol. 2019; 94(3): 363–377.
  14. Stone RM, Manley PW, Larson RA, et al. Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis. Blood Adv. 2018; 2(4): 444–453.
  15. Gotlib J, Kluin-Nelemans HC, George TI, et al. Efficacy and safety of midostaurin in advanced systemic mastocytosis. N Engl J Med. 2016; 374(26): 2530–2541.

Hematology in Clinical Practice